Neurocrine logo

Neurocrine Stock

StockStock
ISIN: US64125C1099
Ticker: NBIX
US64125C1099
NBIX

Price

Frequently asked questions

What is Neurocrine's market capitalization?

The market capitalization of Neurocrine is $12.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Neurocrine's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Neurocrine is 34.06. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Neurocrine?

Neurocrine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.734. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Neurocrine's stock?

Currently, 25 analysts cover Neurocrine's stock, with a consensus target price of $160.52. Analyst ratings provide insights into the stock's expected performance.

What is Neurocrine's revenue over the trailing twelve months?

Over the trailing twelve months, Neurocrine reported a revenue of $2.24B.

What is the EBITDA for Neurocrine?

Neurocrine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $614.00M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Neurocrine?

Neurocrine has a free cash flow of $440.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Neurocrine's stock?

The 5-year beta for Neurocrine is 0.34. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Neurocrine have, and what sector and industry does it belong to?

Neurocrine employs approximately 1,700 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Neurocrine's shares?

The free float of Neurocrine is 99.60M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$12.88B

5Y beta

 
0.34

EPS (TTM)

 
$3.734

Free Float

 
99.60M

P/E ratio (TTM)

 
34.06

Revenue (TTM)

 
$2.24B

EBITDA (TTM)

 
$614.00M

Free Cashflow (TTM)

 
$440.10M

Pricing

1D span
$126.25$128.37
52W span
$107.84$157.98

Analyst Ratings

The price target is $160.52 and the stock is covered by 25 analysts.

Buy

20

Hold

4

Sell

1

Information

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

1,700

Biotechnology & Drugs

Health Care

Identifier

ISIN

US64125C1099

Primary Ticker

NBIX

Knockouts

Join the conversation